GLP-2 is strictly for laboratory research and is commonly employed in the following investigational areas:

Intestinal Adaptation & Tissue Engineering Models

GLP-2 is extensively utilized as a chemical probe to study intestinal adaptive growth following structural resection or chemical injury. Researchers employ this peptide to quantify mucosal hyperplasia, increased crypt-villus height, and restored absorptive capacity in isolated gastrointestinal models.

Cellular Survival and Apoptosis Assays

In vitro studies employ GLP-2 to observe its cytoprotective impact on intestinal epithelial cells. Investigations focus on how GLP-2 receptor activation rapidly suppresses caspase-3 activation and upregulates Bcl-2, effectively reducing cellular apoptosis and increasing cell survival rates.

Gastrointestinal Barrier Function and Bioenergetics

Experimental models utilize this compound to study its role in reducing epithelial permeability and increasing mesenteric blood flow. Researchers investigate how GLP-2 modulates nitric oxide production and coordinates the transport of intracellular lipids and dietary nutrients across the apical membrane of enterocytes.

Pathway / Mechanistic Context

The primary mechanism of action for GLP-2 in research settings involves the targeted activation of the GLP-2 receptor (GLP-2R).

• Receptor Activation: Under experimental conditions, GLP-2 binds to GLP-2R, a G protein-coupled receptor predominantly localized in the subepithelial networks of the gut.
• Signal Transduction: This binding event stimulates adenylate cyclase, leading to the accumulation of intracellular cyclic AMP (cAMP) and subsequent protein kinase A (PKA) activation. It simultaneously triggers the extracellular signal-regulated kinase (ERK1/2) pathway.
• Resulting Flux: This divergent signaling cascade initiates cytoprotective mechanisms via the suppression of apoptotic factors, while also driving cellular proliferation and mediating localized expansion of the mucosal epithelium.

Preclinical Research Summary

Published preclinical literature documents investigations of GLP-2 across multiple experimental models for pathway characterization:

• Mucosal Growth: Studies in massive intestinal resection rat models demonstrate that GLP-2 administration significantly increases crypt-villus height, DNA and protein content, and overall mucosal mass in both the jejunum and ileum.
• Apoptosis Inhibition: Research indicates that early intracellular signaling following GLP-2 exposure effectively inhibits pro-apoptotic mechanisms in neonatal and adult intestinal cell models.
• Barrier Integrity: Data from in vivo assays suggest that sustained augmentation of GLP-2 signaling integrates nutrient-derived signals to optimize mucosal integrity, energy absorption, and adaptation to mucosal damage.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Drucker, D. J., & Yusta, B. (2014). Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annual review of physiology, 76, 561-583. https://doi.org/10.1146/annurev-physiol-021113-170317
• Burrin, D. G., et al. (2006). GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets. American Journal of Physiology-Endocrinology and Metabolism.https://journals.physiology.org/doi/full/10.1152/ajpendo.00129.2006
• Scott, R. B., et al. (1998). GLP-2 augments the adaptive response to massive intestinal resection in rat. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.1998.275.5.G911
• Drucker, D. J., et al. (2006). Glucagon-like Peptide-2. Annual Review of Nutrition, 26, 391-411.https://www.annualreviews.org/content/journals/10.1146/annurev.nutr.26.061505.111223

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.